Clinical Trial: Buparlisib (BKM120) In Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Nervous System Lymphoma (SCNSL)
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: A Phase II Trial Of Buparlisib (BKM120) In Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Ne
Brief Summary: The purpose of this study is to find out what effects, good and/or bad, Buparlisib (also known as BKM120) has on lymphoma and the central nervous system.
Detailed Summary:
Sponsor: Memorial Sloan Kettering Cancer Center
Current Primary Outcome: progression free survival [ Time Frame: up to 24 weeks ]
Original Primary Outcome: Same as current
Current Secondary Outcome: Number of Adverse events that occur [ Time Frame: 2 years ]
Original Secondary Outcome: Same as current
Information By: Memorial Sloan Kettering Cancer Center
Dates:
Date Received: November 21, 2014
Date Started: November 20, 2014
Date Completion:
Last Updated: February 9, 2017
Last Verified: February 2017